James Treace - Nov 15, 2022 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa O. Taylor as Attorney in Fact for James Treace
Stock symbol
TMCI
Transactions as of
Nov 15, 2022
Transactions value $
-$1,014,692
Form type
4
Date filed
3/29/2024, 09:55 PM
Previous filing
Oct 21, 2022
Next filing
Dec 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Sale -$936K -46.5K -4.28% $20.12 1.04M Nov 15, 2022 Direct F1, F2
transaction TMCI Common Stock Sale -$33.9K -1.6K -0.15% $21.18 1.04M Nov 15, 2022 Direct F1, F3
transaction TMCI Common Stock Sale -$4.39K -200 -0.02% $21.97 1.04M Nov 15, 2022 Direct F1
transaction TMCI Common Stock Sale -$40.8K -1.7K -0.16% $24.02 1.04M Nov 15, 2022 Direct F1, F4
holding TMCI Common Stock 556K Nov 15, 2022 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $19.55 to $20.4600 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $20.6200 to $21.5400 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.6100 to $24.6000 inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.